Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(50.0%)
Phase 2
2(33.3%)
N/A
1(16.7%)
6Total
Phase 1(3)
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01377909Phase 1Terminated

HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity

Role: lead

NCT00487318Phase 2Completed

Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin

Role: lead

NCT00994773Phase 1Completed

Simvastatin for the Treatment of Chronic Hepatitis B

Role: lead

NCT00441493Not ApplicableCompleted

Fluvastatin Versus Hepatitis C Virus

Role: lead

NCT00749138Phase 1Completed

Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy

Role: lead

NCT00446940Phase 2Completed

Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C

Role: lead

All 6 trials loaded